Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Interventions: NT 201, Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 11 more

Conditions: Diet, Healthy, Food, Nutrition, Intensive Care, Abdominal Trauma, Surgery, Intra-abdominal Infection, Sepsis, Ischemic Bowel, Vascular, Penetrating Abdominal Trauma, Enteral Feeding, Oral
Interventions: Nutrition Ecosystem pathway, Comparator; Combination Product · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metastatic Colorectal Cancer
Interventions: FOLFIRI Regimen, Sotorasib, Panitumumab, Bevacizumab-awwb; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 26
States / cities: Chandler, Arizona • Fullerton, California • Long Beach, California + 21 more

Conditions: HIV Infections
Interventions: Profectus HIV MAG pDNA vaccine, IL-12, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 13
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 8 more

Conditions: Acute Hypoxemic Respiratory Failure
Interventions: L-Citrulline, Placebo; Drug
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Staphylococcus Aureus
Interventions: NDV-3A, Placebo; Biological
Lead sponsor: NovaDigm Therapeutics, Inc.; Industry
Eligibility: 17 Years to 35 Years · Male only
Enrollment: 382 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Fort Benning, Georgia

Conditions: Systemic Lupos Erythematosus, SLE
Interventions: BIIB068, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Cancer
Interventions: protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy; Genetic · Other · Procedure
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: Up to 120 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Military Operational Stress Reaction, Malnutrition (Calorie), Weight Loss, Muscle Wasting
Interventions: Protein, High-Protein, and Control; Dietary Supplement
Lead sponsor: United States Army Research Institute of Environmental Medicine; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Marine Corps Base Camp Lejeune, North Carolina

Conditions: Lymphoma, Large B-Cell, Diffuse
Interventions: lenalidomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, prednisone, vincristine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 22
States / cities: Fayetteville, Arkansas • Orange, California • Sacramento, California + 16 more

Conditions: Metastatic Breast Cancer
Interventions: Everolimus, Bevacizumab, Paclitaxel, Placebo; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 15
States / cities: LaVerne, California • Norwich, Connecticut • Aventura, Florida + 11 more

Conditions: Vaccine Reaction
Interventions: FMP013, ALFQ; Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Glabellar Frown Lines
Interventions: Botulinum Toxins, Type A, Placebos; Biological
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 15
States / cities: Birmingham, Alabama • Beverly Hills, California • Newport Beach, California + 11 more

Conditions: Dry Eye
Interventions: Cyclosporine, Artificial tear; Drug
Lead sponsor: Vishal Jhanji; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Type 2 Diabetes Mellitus
Interventions: Ranolazine, Placebo, Exenatide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 3
States / cities: Chula Vista, California • Miami, Florida • Orlando, Florida

Conditions: Alzheimer Disease
Interventions: NPT088, Placebo; Drug
Lead sponsor: Proclara Biosciences, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 23
States / cities: Costa Mesa, California • Fullerton, California • Long Beach, California + 20 more

Conditions: Psoriatic Arthritis
Interventions: CNTO 1275 63 mg, Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 12
States / cities: Macon, Georgia • Boise, Idaho • Normal, Illinois + 9 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: ABT-263, rituximab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 48
States / cities: Alhambra, California • Antioch, California • Berkeley, California + 38 more

Conditions: Sickle Cell Anemia, Sickle ß0-Thalassemia
Interventions: L-glutamine, Placebo; Drug
Lead sponsor: Emmaus Medical, Inc.; Industry
Eligibility: 5 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 31
States / cities: Mobile, Alabama • Phoenix, Arizona • Inglewood, California + 23 more

Conditions: Alzheimer's Disease
Interventions: Sagramostim, Saline -- placebo comparator; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 55 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Anemia, Sickle Cell
Interventions: Glutamine, Placebo; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 18 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Fatigue
Interventions: Creatine Monohydrate, Control; Dietary Supplement
Lead sponsor: Ward Dobbs; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: La Crosse, Wisconsin

Conditions: Non-Small Cell Lung Cancer
Interventions: Osimertinib, Cisplatin, Carboplatin, Placebo, Pemetrexed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 12
States / cities: Duarte, California • Irvine, California • San Francisco, California + 9 more

Conditions: Cerebral Aneurysm Unruptured, Cerebral Aneurysm Ruptured
Interventions: Active SRP cases, Control cases; Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

The PASTDUe Nutrition Ecosystem Project (PASTDUe)

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19

Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization

A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

Effects of Protein Supplementation on Lean Body Mass Recovery From Extreme Military Training

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy Adults

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

Tear Film Markers in Dry Eye Syndrome

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease

An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease

Trial of Oral Glutamine in Patients With Sickle Cell Anemia

The Effects of Nutritional Supplementation on Occupational Performance in Firefighters

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Surgical Theater's Surgery Rehearsal Platform